NASDAQ:OPK - Opko Health Stock Price, Forecast & News

$1.56

-0.03 (-1.89 %)

(As of 01/20/2020 11:22 AM ET)

Add

Compare

Today's Range

$1.56

Now: $1.56▼

$1.63

50-Day Range

$1.44

MA: $1.53▼

$1.64

52-Week Range

$1.33

Now: $1.56▼

$3.87

Volume3.65 million shs

Average Volume3.56 million shs

Market Capitalization$1.04 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.21

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:OPK

Previous Symbol

CUSIP68375N10

CIK944809

Webhttp://www.opko.com/

Phone305-575-4100

Debt

Debt-to-Equity Ratio0.14

Current Ratio1.08

Quick Ratio0.90

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$990.30 million

Price / Sales1.05

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.06 per share

Price / Book0.51

Profitability

EPS (Most Recent Fiscal Year)($0.25)

Net Income$-153,040,000.00

Net Margins-30.98%

Return on Equity-14.42%

Return on Assets-10.10%

Miscellaneous

Employees5,690

Outstanding Shares665,600,000

Market Cap$1.04 billion

Next Earnings Date2/26/2020 (Estimated)

OptionableOptionable

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.

Opko Health (NASDAQ:OPK) Frequently Asked Questions

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) announced its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biotechnology company had revenue of $228.80 million for the quarter, compared to analyst estimates of $225.40 million. Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.42%. Opko Health's quarterly revenue was down 8.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.05) EPS. View Opko Health's Earnings History.

When is Opko Health's next earnings date?

Opko Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Opko Health.

What price target have analysts set for OPK?

2 Wall Street analysts have issued 12 month price targets for Opko Health's shares. Their forecasts range from $2.50 to $4.00. On average, they expect Opko Health's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View Analyst Price Targets for Opko Health.

What is the consensus analysts' recommendation for Opko Health?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:

1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019)
2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)

Has Opko Health been receiving favorable news coverage?

News headlines about OPK stock have trended positive on Monday, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opko Health earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Opko Health.

Are investors shorting Opko Health?

Opko Health saw a increase in short interest in December. As of December 31st, there was short interest totalling 80,770,000 shares, an increase of 5.5% from the December 15th total of 76,560,000 shares. Based on an average daily volume of 5,420,000 shares, the days-to-cover ratio is presently 14.9 days. Approximately 20.2% of the shares of the stock are sold short. View Opko Health's Current Options Chain.

Who are some of Opko Health's key competitors?

Some companies that are related to Opko Health include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), Bausch Health Companies (BHC) and Alibaba Group (BABA).

Who are Opko Health's key executives?

Opko Health's management team includes the folowing people:

Dr. Phillip Frost, Chairman & CEO (Age 83)
Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

Who are Opko Health's major shareholders?

Opko Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include RK Asset Management LLC (0.18%) and Alpine Global Management LLC (0.01%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.

Which major investors are selling Opko Health stock?

OPK stock was sold by a variety of institutional investors in the last quarter, including RK Asset Management LLC. View Insider Buying and Selling for Opko Health.

Which major investors are buying Opko Health stock?

OPK stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $1.56.

How big of a company is Opko Health?

Opko Health has a market capitalization of $1.04 billion and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health.

What is Opko Health's official website?

The official website for Opko Health is http://www.opko.com/.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]

MarketBeat Community Rating for Opko Health (NASDAQ OPK)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		437 (Vote Outperform)
Underperform Votes:		415 (Vote Underperform)
Total Votes:		852

MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: What is the outlook for the FAANG stocks?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.